GlassScriptPhysician profile
Deborah Consbruck
NPI 1245503671
$2,209.25
in general payments reported to CMS, 2019-2025
20 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $140 · 2021: $272 · 2022: $108 · 2023: $452 · 2024: $768 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $247.60 | 2024 | Miebo, Xiidra |
| Rxsight INC | $241.55 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Amgen INC. | $171.04 | 2024 | Tepezza |
| Abbvie INC. | $147.07 | 2024-2025 | |
| Alcon Vision LLC | $139.41 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $129.15 | 2023 | Acuvue |
| Sun Pharmaceutical Industries INC. | $122.31 | 2020 | |
| Glaukos Corporation | $122.15 | 2024 | Ce-Marked Kxla System |
| Coopervision INC. | $117.94 | 2023-2024 | Misight Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Aerie Pharmaceuticals, INC. | $113.27 | 2019 | |
| Oyster Point Pharma, INC. | $105.33 | 2024-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $97.54 | 2019 | |
| Visionix USA, INC | $90.90 | 2022 | |
| Allergan, INC. | $84.88 | 2021-2022 | |
| Dompe US, INC. | $75.79 | 2021-2025 | Oxervate |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $69.15 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $43.92 | 2023 | Tepezza |
| Harrow Eye, LLC | $39.00 | 2025 | Vevye |
| Astellas Pharma US INC | $26.92 | 2024 | Izervay |
| Kala Pharmaceuticals, INC. | $24.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Consbruck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.